CL2022000087A1 - Anticuerpo anti-tau y uso del mismo - Google Patents

Anticuerpo anti-tau y uso del mismo

Info

Publication number
CL2022000087A1
CL2022000087A1 CL2022000087A CL2022000087A CL2022000087A1 CL 2022000087 A1 CL2022000087 A1 CL 2022000087A1 CL 2022000087 A CL2022000087 A CL 2022000087A CL 2022000087 A CL2022000087 A CL 2022000087A CL 2022000087 A1 CL2022000087 A1 CL 2022000087A1
Authority
CL
Chile
Prior art keywords
tau antibody
tau
antibody
Prior art date
Application number
CL2022000087A
Other languages
English (en)
Spanish (es)
Inventor
Seung-Yong Yoon
Original Assignee
Adel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel Inc filed Critical Adel Inc
Publication of CL2022000087A1 publication Critical patent/CL2022000087A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
CL2022000087A 2019-07-15 2022-01-12 Anticuerpo anti-tau y uso del mismo CL2022000087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190085233 2019-07-15

Publications (1)

Publication Number Publication Date
CL2022000087A1 true CL2022000087A1 (es) 2023-03-10

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000087A CL2022000087A1 (es) 2019-07-15 2022-01-12 Anticuerpo anti-tau y uso del mismo

Country Status (16)

Country Link
US (1) US20220204601A1 (https=)
EP (1) EP4001305A4 (https=)
JP (1) JP7595061B2 (https=)
KR (1) KR102196840B1 (https=)
CN (1) CN114430744B (https=)
AU (1) AU2020313751A1 (https=)
BR (1) BR112022000719A2 (https=)
CA (1) CA3143811A1 (https=)
CL (1) CL2022000087A1 (https=)
GB (1) GB2600599B (https=)
IL (1) IL289813A (https=)
MX (1) MX2022000603A (https=)
MY (1) MY207132A (https=)
PH (1) PH12022550106A1 (https=)
TW (1) TW202116801A (https=)
WO (1) WO2021010712A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US20240376188A1 (en) * 2021-09-09 2024-11-14 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
US20250134952A1 (en) 2021-09-20 2025-05-01 Institut National de la Santé et de la Recherche Médicale Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023229445A1 (ko) * 2022-05-27 2023-11-30 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
EP4631975A1 (en) 2022-12-08 2025-10-15 Adel Inc. Fusion comprising anti-tau antibody and peptide and use thereof
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
RU2644242C2 (ru) * 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
TWI669314B (zh) * 2015-02-26 2019-08-21 美國禮來大藥廠 針對tau之抗體及其用途
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Also Published As

Publication number Publication date
GB2600599B (en) 2025-05-21
MY207132A (en) 2025-01-31
AU2020313751A1 (en) 2022-02-10
EP4001305A1 (en) 2022-05-25
MX2022000603A (es) 2022-05-20
CN114430744A (zh) 2022-05-03
CN114430744B (zh) 2024-06-21
BR112022000719A2 (pt) 2022-03-29
EP4001305A9 (en) 2023-05-24
EP4001305A4 (en) 2022-10-12
GB2600599A8 (en) 2024-12-25
CA3143811A1 (en) 2021-01-21
TW202116801A (zh) 2021-05-01
PH12022550106A1 (en) 2022-11-21
IL289813A (en) 2022-03-01
JP2022541539A (ja) 2022-09-26
WO2021010712A1 (ko) 2021-01-21
KR102196840B1 (ko) 2020-12-30
JP7595061B2 (ja) 2024-12-05
GB2600599A (en) 2022-05-04
US20220204601A1 (en) 2022-06-30
GB202201160D0 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CO2019001980A2 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP3822289A4 (en) ANTI-SIRP-ALPHA ANTIBODIES
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX392916B (es) Estructuras de nanofibra y métodos de uso de las mismas
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
EP3932949C0 (en) ANTI-CD25 ANTIBODY AND ITS USE
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof